Lamotrigine
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Lamotrigine: From Epilepsy to Trigeminal Neuralgia
One-Sentence Summary
Lamotrigine is a broad-spectrum anticonvulsant originally developed for epilepsy (seizure disorders) and later established for bipolar disorder. The TxGNN model, supported by pharmacological literature, predicts it may be effective for Trigeminal Neuralgia, with 4 clinical trials (including 2 lamotrigine-specific completed studies) and 19 publications currently supporting this direction.
Note on model ranking: TxGNN’s single highest-scoring node (“trigeminal nerve neoplasm,” score 99.97%) is flagged in the evidence pack’s own rationale as a likely knowledge-graph confusion with “trigeminal neuralgia” — its only supporting literature is a general neuralgia review and an unrelated tumor case report, with no lamotrigine-specific evidence (Evidence Level L5, Hold). This report instead focuses on the second-ranked, substantively evidenced candidate, trigeminal neuralgia, which carries real drug-specific clinical trial data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy / seizure disorders (and bipolar disorder) — per literature evidence in this pack; no TFDA license text available |
| Predicted New Indication | Trigeminal Neuralgia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L2 |
| US Market Status | Not marketed (0 licenses on record in this evidence pack) |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Lamotrigine is a voltage-gated sodium channel blocker that inhibits glutamate release and stabilizes neuronal membranes. According to the evidence pack’s mechanistic rationale, this action can suppress abnormal discharges at the trigeminal ganglion — the same underlying mechanism exploited by carbamazepine and oxcarbazepine, the established first-line drugs for trigeminal neuralgia.
Trigeminal neuralgia and epilepsy share a common therapeutic class: both are neuronal hyperexcitability disorders responsive to sodium-channel-blocking anticonvulsants. This mechanistic overlap is why several second-generation antiepileptics, lamotrigine included, have been trialed as add-on or alternative therapy when first-line agents fail or are poorly tolerated.
This is not purely theoretical extrapolation — the European Academy of Neurology guideline (PMID 30860637, a Tier 1 guideline source) already lists lamotrigine among treatment options for TN, and two completed clinical trials (a placebo-controlled add-on study and a head-to-head Phase 2/3 comparison against carbamazepine) provide direct human evidence, albeit in small cohorts.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00203229 | N/A | Completed | 20 | Double-blind, placebo-controlled add-on study of lamotrigine (Lamictal) safety and efficacy in reducing trigeminal neuralgia attacks |
| NCT00913107 | Phase 2/3 | Completed | 21 | Head-to-head comparison of lamotrigine vs. carbamazepine efficacy and safety in trigeminal neuralgia |
| NCT00243152 | N/A | Completed | 6 | fMRI study evaluating lamotrigine’s effect on neuropathic facial pain / neuralgia |
| NCT04996199 | Phase 4 | Unknown | 132 | Comparative efficacy of carbamazepine vs. oxcarbazepine in TN (background comparator trial; does not use lamotrigine) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21621166 | 2011 | Comparative study | Journal of the Chinese Medical Association | Companion publication to NCT00913107; evaluated efficacy/safety of lamotrigine vs. carbamazepine in TN patients |
| 30860637 | 2019 | Guideline | European Journal of Neurology | European Academy of Neurology guideline on TN management, including pharmacotherapy recommendations |
| 38870050 | 2024 | Review | Expert Review of Neurotherapeutics | Update on TN pharmacotherapy; lamotrigine noted among options beyond first-line carbamazepine/oxcarbazepine |
| 37892981 | 2023 | Systematic review | Biomedicines | Umbrella review of drug therapies for TN and their efficacy/side-effect profiles |
| 31908187 | 2020 | Review | Molecular Pain | Overview of TN pathophysiology through pharmacological treatment |
| 39365662 | 2025 | Cohort | Pain | Nationwide Danish disease-trajectory study of TN comorbidities (7.2M individuals) |
| 34108244 | 2021 | Review | Practical Neurology | Practical guide to TN diagnosis and management |
| 30081317 | 2018 | Case report | Multiple Sclerosis and Related Disorders | Refractory TN in an MS patient successfully treated with pregabalin + lamotrigine combination |
| 38246671 | 2024 | Review | No Shinkei Geka (Neurological Surgery) | Japanese review of TN pharmacotherapy listing lamotrigine as an off-label alternative |
| 25299564 | 2014 | Clinical evidence review | BMJ Clinical Evidence | Overview of TN diagnosis, prognosis, and treatment options |
US Market Information
No FDA/regulatory license records are present in this evidence pack (total_licenses = 0). This is flagged as a data gap (DG001: TFDA label/warning data blocking) rather than a confirmed absence of marketing authorization — regulatory data collection for this drug should be re-verified before relying on this status.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed placebo-controlled add-on trial and a completed Phase 2/3 head-to-head trial against carbamazepine provide direct, drug-specific evidence for lamotrigine in trigeminal neuralgia, reinforced by guideline-level literature and a consistent sodium-channel-blocking mechanism shared with established TN therapies. However, both pivotal trials are small (N=20 and N=21), and no confirmatory large-scale Phase 3 RCT exists — guardrails are warranted before broader clinical application.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001 — currently blocking safety evaluation)
- Detailed mechanism of action data from DrugBank (DG002)
- A larger, confirmatory Phase 3 RCT in trigeminal neuralgia
- Verification of actual US/Taiwan market and licensing status, given the apparent inconsistency between “0 licenses on record” and lamotrigine’s well-established clinical use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.